Roka Bio Q2 Revenues More than Double; Leerink Initiates Coverage with Outperform Rating | GenomeWeb

NEW YORK (GenomeWeb) – Molecular diagnostics firm Roka Bioscience today reported that its second quarter revenues more than doubled year over year.

The Warren, NJ-based firm, which recently became a publicly traded company, reported revenues of $1.4 million for the three months ended June 30, up from $671,000 a year ago as the number of Atlas instruments placed with commercial customers and the commercial use of the platforms increased. As of the end of the quarter, Roka had 36 instrument placements, up from 21 in the year-ago period, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV. 

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.